|
|
Antimicrob Agents Chemother. 1975 February; 7(2): 146–152. | PMCID: PMC429094 |
Bacteriological Studies with Morphine-Like Narcotics: Relevance to Narcotic Actions in Mammals? Alan D. Wolfe, John G. Olenick, and Fred E. Hahn 1Department of Molecular Biology, Walter Reed Army Institute of Research, Washington, D.C. 20012 Abstract A search for active bacterial growth inhibitors among seven highly potent morphine-like narcotics revealed that NIH 7591 and etorphine inhibited the rates of growth of Escherichia coli by 50% at 1.9 × 10−4 M. Bacterial cultures escaped from growth inhibition by NIH 7591 after times which were proportional to the drug concentrations and inversely proportional to the initial bacterial densities. Populations of E. coli could adapt to resist and cross-resist growth inhibitions by NIH 7591 and phenazocine. Resistance was lost after growth in drug-free medium for a few doubling times. The agonist-antagonist pair, etorphine and diprenorphine, inhibited growth of E. coli additively without any indication of antagonism. Actions of narcotics in bacteria is considered a theme in its own right. Full text Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (970K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References. These references are in PubMed. This may not be the complete list of references from this article. - Bentley KW, Hardy DG. Novel analgesics and molecular rearrangements in the morphine-thebaine group. 3. Alcohols of the 6,14-endo-ethenotetrahydrooripavine series and derived analogs of N-allylnormorphine and -norcodeine. J Am Chem Soc. 1967 Jun 21;89(13):3281–3292. [PubMed]
- Blane GF, Dugdall D. Interactions of narcotic antagonists and antagonist-analgesics. J Pharm Pharmacol. 1968 Jul;20(7):547–552. [PubMed]
- Boquet P, Devynck M, Aurelle H, Fromageot P. On the bactericidal action of levallorphan. Irreversible alterations of the plasmic membrane. Eur J Biochem. 1971 Aug 25;21(4):536–541. [PubMed]
- Boquet PL, Devynvk MA, Fromageot P. Involvement of the RC locus in RNA synthesis inhibition by levallorphan in E. coli. FEBS Lett. 1971 Mar 22;13(5):279–281. [PubMed]
- Boquet PL, Devynck MA, Monnier C, Fromageot P. Inhibition of stable RNA synthesis by levallorphan in Escherichia coli. Implication of compounds MS I and MS II. Eur J Biochem. 1973 Dec 3;40(1):31–42. [PubMed]
- Connamacher RH, Mandel HG, Hahn FE. Adaptation of populations of Bacillus cereus to tetracycline. Mol Pharmacol. 1967 Nov;3(6):586–594. [PubMed]
- Devynck MA, Boquet PL, Fromageot P. On the mode of action of levallorphan on Escherichia coli: effects on cellular magnesium. Mol Pharmacol. 1971 Nov;7(6):605–610. [PubMed]
- ELION GB, SINGER S, HITCHINGS GH. Antagonists of nucleic acid derivatives. VIII. Synergism in combinations of biochemically related antimetabolites. J Biol Chem. 1954 Jun;208(2):477–488. [PubMed]
- Greene R, Magasanik B. The mode of action of levallorphan as an inhibitor of cell growth. Mol Pharmacol. 1967 Sep;3(5):453–472. [PubMed]
- Harshman RB, Yamazaki H. Levallorphan-induced accumulation of ppGpp in Escherichia coli. Biochemistry. 1972 Apr 11;11(8):1363–1366. [PubMed]
- Knape H, Boquet PL, Röschenthaler R. Inhibition of amino acid transport in Escherichia coli cells and its cell membranes. FEBS Lett. 1972 Jan 1;19(4):311–314. [PubMed]
- LOEWE S. Antagonisms and antagonists. Pharmacol Rev. 1957 Jun;9(2):237–242. [PubMed]
- Löser R, Boquet PL, Röschenthaler R. Inhibition of R-factor transfer by levallorphan. Biochem Biophys Res Commun. 1971 Oct 1;45(1):204–211. [PubMed]
- Lowney LI, Schulz K, Lowery PJ, Goldstein A. Partial purification of an opiate receptor from mouse brain. Science. 1974 Feb 22;183(126):749–753. [PubMed]
- MELLETT LB, WOODS LA. ANALGESIA AND ADDICTION. Fortschr Arzneimittelforsch. 1963;5:155–267. [PubMed]
- MILLER JW, ELLIOTT HW. Rat tissue levels of carbon-14 labeled analgetics as related to pharmacological activity. J Pharmacol Exp Ther. 1955 Mar;113(3):283–291. [PubMed]
- MOYED HS. Interference with feedback control of enzyme activity. Cold Spring Harb Symp Quant Biol. 1961;26:323–329. [PubMed]
- Raab C, Röschenthaler R. Inhibition of adsorption and replication of the RNA-phage MS-2 in Escherichia coli C 3000 by levallorphan. Biochem Biophys Res Commun. 1970 Dec 24;41(6):1429–1436. [PubMed]
- Rang HP. Drug receptors and their function. Nature. 1971 May 14;231(5298):91–96. [PubMed]
- SIMON EJ. INHIBITION OF BACTERIAL GROWTH BY DRUGS OF THE MORPHINE SERIES. Science. 1964 May 1;144:543–544. [PubMed]
- Simon EJ, Cohen SS, Raina A. Polyamines and inhibition of RNA synthesis in E. coli by levorphanol. Biochem Biophys Res Commun. 1966 Aug 12;24(3):482–488. [PubMed]
- Simon EJ, Schapira L, Wurster N. Effect of levorphanol on putrescine transport in Escherichia coli. Mol Pharmacol. 1970 Nov;6(6):577–587. [PubMed]
- SIMON EJ, VANPRAAG D. INHIBITION OF RNA SYNTHESIS IN ESCHERICHIA COLI BY LEVORPHANOL. Proc Natl Acad Sci U S A. 1964 May;51:877–883. [PubMed]
- WAY EL, ADLER TK. The biological disposition of morphine and its surrogates. I. Bull World Health Organ. 1961;25:227–262. [PubMed]
- WEAVER JR, PATTEE PA. INDUCIBLE RESISTANCE TO ERYTHROMYCIN IN STAPHYLOCOCCUS AUREUS. J Bacteriol. 1964 Sep;88:574–580. [PubMed]
- Wolfe AD, Cook TM, Hahn FE. Antibacterial nitroacridine, Nitroakridin 3582: effects on bacterial growth and macromolecular biosynthesis in vivo. J Bacteriol. 1971 Oct;108(1):320–327. [PubMed]
- Wurster N, Elsbach P, Rand J, Simon EJ. Effects of levorphanol on phospholipid metabolism and composition in Escherichia coli. Biochim Biophys Acta. 1971 Nov 5;248(2):282–292. [PubMed]
- Zimmerman AM. Sensitivity of Amoeba proteus to morphine and N-allylnormorphine. A pressure study. J Protozool. 1967 Aug;14(3):451–455. [PubMed]
|
This article has been